Better Therapeutics Management
Management criteria checks 4/4
Better Therapeutics' CEO is Frank Karbe, appointed in Jul 2022, has a tenure of 2.5 years. total yearly compensation is $557.50K, comprised of 89.7% salary and 10.3% bonuses, including company stock and options. directly owns 0.85% of the company’s shares, worth $46.40. The average tenure of the management team and the board of directors is 2.5 years and 3.3 years respectively.
Key information
Frank Karbe
Chief executive officer
US$557.5k
Total compensation
| CEO salary percentage | 89.7% |
| CEO tenure | 2.5yrs |
| CEO ownership | 0.9% |
| Management average tenure | 2.5yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Better Therapeutics files for FDA approval of new type of digital therapy for diabetes
Sep 22Better Therapeutics GAAP EPS of -$0.42 in-line
Aug 11Better Therapeutics: App-Based Therapeutics, Doesn't Look Novel
May 12Better Therapeutics: Pioneering Prescription Digital Therapeutics Platform For Cardiometabolic Diseases
Nov 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$32m |
| Jun 30 2023 | n/a | n/a | -US$37m |
| Mar 31 2023 | n/a | n/a | -US$39m |
| Dec 31 2022 | US$1m | US$246k | -US$40m |
Compensation vs Market: Frank's total compensation ($USD557.50K) is about average for companies of similar size in the US market ($USD645.37K).
Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.
CEO
Frank Karbe (56 yo)
2.5yrs
Tenure
US$557,500
Compensation
Mr. Frank L. Karbe has been the Chief Executive Officer, President and Director at Better Therapeutics, Inc. since July 5, 2022 and serves its Interim Chief Financial Officer since November 2023. He served...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 3.3yrs | US$119.25k | 35.58% $ 1.9k | |
| CEO, Interim CFO | 2.5yrs | US$557.50k | 0.85% $ 46.4 | |
| Chief Medical Officer | 3.3yrs | US$593.70k | 0.59% $ 32.1 | |
| Chief Product Officer | 3.3yrs | US$558.70k | 0.37% $ 20.0 | |
| Senior VP of Technology & Head of Engineering | no data | no data | no data | |
| Senior Vice President of Market Access | 1.5yrs | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data | |
| Controller | no data | no data | 0.026% $ 1.4 |
2.5yrs
Average Tenure
53.5yo
Average Age
Experienced Management: BTTX's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 3.3yrs | US$119.25k | 35.58% $ 1.9k | |
| CEO, Interim CFO | 2.5yrs | US$557.50k | 0.85% $ 46.4 | |
| Independent Director | 3.3yrs | US$60.50k | 0.018% $ 1.0 | |
| Independent Director | 3.3yrs | US$36.09k | 1.36% $ 74.2 | |
| Independent Director | 3.3yrs | US$159.56k | 0.28% $ 15.4 | |
| Independent Director | 3.3yrs | US$36.34k | 1.98% $ 108.1 | |
| Independent Director | 3.2yrs | US$32.34k | 0.066% $ 3.6 |
3.3yrs
Average Tenure
59yo
Average Age
Experienced Board: BTTX's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 11:04 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Better Therapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Chardan Capital Markets, LLC |
| Thomas Flaten | Lake Street Capital Markets, LLC |
| Rahul Rakhit | LifeSci Capital, LLC |